CD34+Thy+Lin- hematopoietic stem cells data

STMX reported interim results of a Phase I/II trial of its CD34+Thy+Lin- HSCs at the American Society of Hematology meeting in Seattle.

HSCs in multiple myeloma patients recovering from chemotherapy showed that the necessary cells for two transplants per patient were mobilized from 10 of the initial 12 patients. ...